序号 |
标题 |
次数 |
作者 |
发布时间 |
73261 |
Re-cyc-DOTA-sst2-ANT复合物 |
91 |
h |
2024-12-19 |
73262 |
DOTA-SP DOTA-P物质(SP) |
96 |
h |
2024-12-19 |
73263 |
DOTA-MG45 DOTA偶联迷你胃泌素(MG45) |
91 |
h |
2024-12-19 |
73264 |
DOTA-甘露糖胺葡聚糖 DOTA-MADs |
79 |
h |
2024-12-19 |
73265 |
ICG-DOTA 大环配体DOTA修饰吲哚菁绿荧光染料 |
101 |
h |
2024-12-18 |
73266 |
DOTA-SSA 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)-生长抑素类似物(SSA) |
79 |
h |
2024-12-18 |
73267 |
DOTA螯合剂修饰[cPP(1-7) |
140 |
h |
2024-12-18 |
73268 |
DOTA-ALB-24 DOTA-4-(对碘苯基)丁酸酯-24 |
89 |
h |
2024-12-18 |
73269 |
DOTA-GGNle-CycMSH hex DOTA偶联新肽 |
109 |
h |
2024-12-18 |
73270 |
Zr-p-NO2Bn-DOTA异构体 锆-硝基苄基偶联DOTA螯合剂 |
103 |
h |
2024-12-18 |
73271 |
DOTA-PSMA-617 1,4,7,10-四氮杂环十五烷偶联PSMA-617 |
80 |
h |
2024-12-18 |
73272 |
DOTA-VAP-1 螯合剂DOTA偶联VAP-1靶向肽 |
139 |
h |
2024-12-18 |
73273 |
DOTA-GIP-C803 DOTA螯合剂缀合GIPC803肽 |
69 |
h |
2024-12-18 |
73274 |
DOTA-mPS 螯合剂DOTA修饰微米级聚苯乙烯 |
101 |
h |
2024-12-18 |
73275 |
DOTA-HBED-bisphosphonate DOTA-HBED-二膦酸盐 |
98 |
h |
2024-12-18 |
73276 |
CAS号:2226472-28-0 ,DBCO-PEG4-Val-Cit-PAB-PNP |
101 |
WYQ |
2024-12-18 |
73277 |
cas:2112738-09-5, Mal-PEG4-Val-Cit-PAB-PNP |
112 |
WYQ |
2024-12-18 |
73278 |
Mal-PEG8-Val-Cit-PAB-PNP,可以溶解于DCM、DMF、DMSO、THF等有机溶剂,以及水中。 |
120 |
WYQ |
2024-12-18 |
73279 |
Mal-PEG2-Val-Ala-PAB-PNP,含有马来酰亚胺(Mal)官能团、两个单元的聚乙二醇(PEG2)间隔物、缬氨酸(Val)和丙氨酸(Ala)的序列 |
72 |
WYQ |
2024-12-18 |
73280 |
Mal-PEG2-Val-Cit-PABA(CAS号:1662687-83-3) |
92 |
WYQ |
2024-12-18 |
73281 |
CAS号:1096584-62-1, Mal-Val-Cit-PAB-PNP |
68 |
WYQ |
2024-12-18 |
73282 |
Mal-amido-PEG2-Val-Cit-PAB-OH,马来酰亚胺-酰胺-二聚乙二醇-缬氨酸-瓜氨酸-PAB-羟基 |
68 |
WYQ |
2024-12-18 |
73283 |
CAS号:1949793-41-2 ,Mal-amido-PEG4-Val-Cit-PAB-OH |
78 |
WYQ |
2024-12-18 |
73284 |
DOTA-伊班膦酸 DOTA-IBA |
71 |
h |
2024-12-18 |
73285 |
FA-DOTA-PEG-PLGA 叶酸-DOTA-聚乙二醇-聚乳酸-羟基乙酸共聚物 |
81 |
h |
2024-12-18 |
73286 |
DOTA-泛素29-41 |
71 |
h |
2024-12-18 |
73287 |
cas:1226403-39-9,N-(2-(3,4-Difluorophenoxy)ethyl)-4-formylbenzamide |
75 |
kx |
2024-12-18 |
73288 |
Cu-64 DOTA-曲妥珠单抗 Cu-64-Herceptin |
119 |
h |
2024-12-18 |
73289 |
CAS号:2112738-13-1 ,Mal-amido-PEG2-Val-Cit-PAB-PNP |
77 |
WYQ |
2024-12-18 |
73290 |
CAS号:2055041-40-0 , Azido-PEG1-Val-Cit-PAB-OH |
90 |
WYQ |
2024-12-18 |
73291 |
cas:1226006-55-8,N-(2-(3-Ethoxyphenoxy)ethyl)-4-formylbenzamide, ADC试剂 |
66 |
kx |
2024-12-18 |
73292 |
DOTA-LTVSPWY 双功能螯合剂DOTA偶联肽LTVSPWY |
70 |
h |
2024-12-18 |
73293 |
CAS号:2055024-65-0 ,Azido-PEG3-Val-Cit-PAB-OH |
76 |
WYQ |
2024-12-18 |
73294 |
DOTA-CCK-66 大环DOTA偶联CCK2R靶向化合物CCK-66 |
164 |
h |
2024-12-18 |
73295 |
cas:1228153-04-5,4-Formyl-N-(2-(naphthalen-2-yloxy)ethyl)benzamide |
99 |
kx |
2024-12-18 |
73296 |
抗DOTA IgG-scFv BsAb anti-DOTA IgG-scFv BsAb |
113 |
h |
2024-12-18 |
73297 |
cas:1226217-30-6,4-Formyl-N-(2-(4-isopropylphenoxy)ethyl)benzamide |
79 |
kx |
2024-12-18 |
73298 |
DOTA-rL-A9肽 DOTA偶联核定位序列(NLS)-移植的her 2-受体亲和肽 |
95 |
h |
2024-12-18 |
73299 |
cas:796073-59-1,2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
70 |
kx |
2024-12-18 |
73300 |
DOTA-E[c(RGDFK)]2 双功能螯合剂偶联的RGD多肽E[c(RGDfK)]2 |
73 |
h |
2024-12-18 |
73301 |
DBCO-C4-Val-Cit-PABC-PNP,分子式:C46H49N7O10 |
79 |
WYQ |
2024-12-18 |
73302 |
DBCO-(PEG)3-VC-PAB-MMAE,CAS号:57103-68-1 |
53 |
WYQ |
2024-12-18 |
73303 |
cas:1134280-65-1,2,5-Dioxopyrrolidin-1-yl 3-((2,4-difluorobenzyl)oxy)propanoate |
77 |
kx |
2024-12-18 |
73304 |
DBCO-PEG3-acetic-Val-Cit-PAB(二苯并环辛炔) |
83 |
WYQ |
2024-12-18 |
73305 |
cas:1824718-79-7,SPDH, ADC试剂 |
84 |
kx |
2024-12-18 |